06. October 2017

MTG as protein labeling tool



Zedira kits
 
Zedira logo

Transglutaminase-Newsletter | October 2017



Your MTG tool box

To ease your experiments we provide you with an extensive tool box of products around microbial transglutaminase (MTG), an amaizing enzyme for a versatility of applications.

Microbial Transglutaminase

Art. No. Name Unit Price

T001 Microbial (bacterial) transglutaminase
(MTG, recombinantly produced in E. coli,
gene derived from Streptomyces mobaraensis)
25 U
250 U
10x 25 U
500 U
20x 25 U
270 €
2140 €
2140 €
3750 €
3750 €

T178 Microbial transglutaminase with C-terminal His6-Tag
(MTG-His6, recombinantly produced in E. coli,
gene derived from Streptomyces mobaraensis)
25 U
10x 25 U
20x 25 U
370 €
2950 €
5150 €


Activity Assays

Art. No. Name Unit Price

Z009 ZediXclusive Microbial Transglutaminase Assay Kit
(Chromogenic determination of microbial transglutaminase activity at 525 nm)

1 Kit 310 €
M001 MTG-ANiTA-Kit
(Ammonium-NicotinamidADPH-GLDH-Transglutaminase-Assay)
1 Kit 575 €



Inhibitor

Art. No. Name Unit Price

C102 MTG-Blocker
(Inhibition of MTG, IC50 ~ 125 µM)
10 mg
25 mg
210 €
385 €

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • Life Sciences 2019: Post-translational modifications and cell signalling

    17.03.2019 - 18.03.2019
    Nottingham, UK

  • 10th International meeting of the Society for research on the Cerebellum and Ataxias (SRCA)

    16.05.2019 - 17.05.2019
    Sheffield, UK

  • 18th International Celiac Disease Symposium ICDS

    04.09.2019 - 07.09.2019
    Paris, France